Cargando…

Paliperidone palmitate-induced facial angioedema: A case report

BACKGROUND: Paliperidone palmitate is a once-monthly injectable, atypical antipsychotic. To our knowledge, there has been only one report of paliperidone palmitate-induced angioedema presenting with acute laryngeal edema with subsequent respiratory arrest. Here, we present a case report of paliperid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srifuengfung, Maytinee, Sukakul, Thanisorn, Liangcheep, Chanika, Viravan, Natee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642554/ https://www.ncbi.nlm.nih.gov/pubmed/33195656 http://dx.doi.org/10.12998/wjcc.v8.i20.4876

Ejemplares similares

Impact of the COVID-19 pandemic on older adults living in long-term care centers in Thailand, and risk factors for post-traumatic stress, depression, and anxiety
por: Srifuengfung, Maytinee, et al.
Publicado: (2021)

Paliperidone Palmitate-induced Urinary Incontinence: A Case Report
por: Karslıoǧlu, Ersin Hatice, et al.
Publicado: (2016)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Paliperidone palmitate-induced enuresis: a case report
por: Cruz, S., et al.
Publicado: (2022)

Chronic Paronychia and Onychomadesis in Pemphigus Vegetans: An Unusual Presentation in a Rare Autoimmune Disease
por: Sukakul, Thanisorn, et al.
Publicado: (2018)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
por: de Azevedo Avelar, Rita, et al.
Publicado: (2020)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report
por: Cicek, Erdinc, et al.
Publicado: (2017)

A Case of Ileus in a Patient with Schizophrenia Under Paliperidone Palmitate Treatment
por: Can, Serdar Süleyman, et al.
Publicado: (2016)

Long-acting injectable paliperidone palmitate induced severe cutaneous allergic reaction in a patient with first episode delusional disorder tolerating oral paliperidone regimen: a case report
por: Borojevic, Natasa, et al.
Publicado: (2022)

Crippling Side Effects Induced by Paliperidone Palmitate Treatment: A Case Report
por: Al-Mahrouqi, Tamadhir, et al.
Publicado: (2021)

A case report of guardian-consent forced paliperidone palmitate for behavioral disturbance due to traumatic brain injury
por: Douglass, Amber R., et al.
Publicado: (2018)

Five Month-Persistent Extrapyramidal Symptoms following a Single Injection of Paliperidone Palmitate: A Case Report
por: Jang, Seoyoung, et al.
Publicado: (2017)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Paliperidone Palmitate Associated with Necrotizing Deep Tissue Infection and Sepsis Requiring Surgical Intervention
por: Leung, Jonathan G., et al.
Publicado: (2015)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada, Ryohei, et al.
Publicado: (2018)

Effects of Paliperidone Palmitate on Coagulation: An Experimental Study
por: Yılmaz, Enver Demirel, et al.
Publicado: (2014)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance
por: Li, Kanglai, et al.
Publicado: (2021)

Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease
por: Orlins, Zachary, et al.
Publicado: (2021)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012)

Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
por: Bell Lynum, Karimah S., et al.
Publicado: (2018)

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder
por: Fu, Dong-Jing, et al.
Publicado: (2016)

Primum non nocere; the importance of evaluating the effect of treatment and considering side effects
por: Sukakul, Thanisorn, et al.
Publicado: (2020)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Acute Dystonia With Rhabdomyolysis Induced by Paliperidone Palmitate: A Rare Adverse Effect
por: Allena, Nishant, et al.
Publicado: (2022)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence
por: Greenberg, William M., et al.
Publicado: (2015)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
por: Luo, Rui, et al.
Publicado: (2023)

Paliperidone induced neutropenia in first episode psychosis: a case report
por: Martos, Natalie, et al.
Publicado: (2021)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
por: Escobedo-Aedo, P. J., et al.
Publicado: (2023)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang, Fan, et al.
Publicado: (2015)

Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia
por: Zhang, Hongyan, et al.
Publicado: (2017)

Alternative initiations with 6-monthly paliperidone palmitate. A descriptive study
por: Sobrino, O. C., et al.
Publicado: (2023)

Alternative initiations with 6-monthly paliperidone palmitate. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_899rbqgrntisphesma3dmqf519